Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMR7OGL)

Drug Name
ABT-239 Drug Info
Synonyms 4-[2-[2-(2-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl]benzonitrile
Cross-matching ID
PubChem CID
9818903
ChEBI ID
CHEMBL351231
CAS Number
CAS 460746-46-7
TTD Drug ID
D04LSD

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Hematopoietic cell lineage 2.02 0.00e+0 90/99 (90.91%) IL7R;CD44;ANPEP;...
Staphylococcus aureus infection 1.99 1.18e-2 72/95 (75.79%) KRT15;KRT19;KRT18;...
Other types of O-glycan biosynthesis 1.86 2.75e-2 29/47 (61.7%) GALNT7;GALNT3;RFNG;...
Mucin type O-glycan biosynthesis 1.81 4.42e-2 20/36 (55.56%) GALNT7;GALNT3;GCNT3;...
Nitrogen metabolism -1.64 3.00e-2 16/17 (94.12%) CA14;CA9;CA2;...
Histidine metabolism -1.65 3.10e-2 16/22 (72.73%) MAOB;ALDH3A2;ASPA;...
Tyrosine metabolism -1.67 2.38e-2 30/36 (83.33%) ADH6;TYR;ADH1B;...
Drug metabolism -1.72 1.75e-2 78/151 (51.66%) ADH6;CYP1A2;CYP2E1;...
Metabolism of xenobiotics by cytochrome P450 -1.73 1.75e-2 49/77 (63.64%) ADH6;CYP1A2;CYP2E1;...
Thermogenesis -1.73 1.80e-2 173/232 (74.57%) SMARCE1;COX6C;NPPB;...
Non-alcoholic fatty liver disease -1.73 1.86e-2 126/155 (81.29%) EIF2S1;COX6C;PRKAA1;...
Diabetic cardiomyopathy -1.73 1.98e-2 162/203 (79.8%) NDUFS4;SDHD;NDUFA7;...
Pathways of neurodegeneration -1.74 1.94e-2 354/475 (74.53%) PSMD4;NDUFS4;PDYN;...
Amyotrophic lateral sclerosis -1.77 1.61e-2 267/364 (73.35%) PSMD4;NDUFS4;SDHD;...
Fatty acid degradation -1.78 1.66e-2 40/43 (93.02%) ADH1B;ACSL4;ADH1A;...
Ferroptosis -1.79 1.60e-2 36/41 (87.8%) SLC39A14;MAP1LC3B;ACSL4;...
Proteasome -1.83 1.21e-2 44/46 (95.65%) IFNG;PSMB6;PSMD6;...
Porphyrin and chlorophyll metabolism -1.85 8.32e-3 23/43 (53.49%) BLVRB;ALAS1;UGT2B17;...
Alzheimer disease -1.86 4.62e-3 279/369 (75.61%) PSMD4;NDUFS4;SDHD;...
Prion disease -1.94 1.04e-3 209/273 (76.56%) PSMC4;LAMC1;ATP5F1E;...
Retinol metabolism -1.99 1.19e-3 41/68 (60.29%) AOX1;ALDH1A2;DHRS9;...
PPAR signaling pathway -2.00 1.39e-3 66/74 (89.19%) ME3;PCK1;MMP1;...
Mineral absorption -2.02 1.66e-3 48/60 (80%) ATP2B2;ATP1A2;S100G;...
Huntington disease -2.09 0.00e+0 233/306 (76.14%) SLC1A2;POLR2J;PSMD4;...
Oxidative phosphorylation -2.20 0.00e+0 93/133 (69.92%) NDUFS4;SDHD;NDUFA7;...
Parkinson disease -2.25 0.00e+0 176/249 (70.68%) PSMD4;NDUFS4;SDHD;...
Ribosome -2.34 0.00e+0 113/158 (71.52%) RPS29;RPL22;RPS15A;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H